Literature DB >> 11474297

Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei.

I M Shih1, H Yan, D Speyrer, B M Shmookler, P H Sugarbaker, B M Ronnett.   

Abstract

Pseudomyxoma peritonei (PMP) is a clinical syndrome characterized by mucinous ascites and peritoneal lesions composed of histologically bland to low-grade adenomatous mucinous epithelium within pools of extracellular mucin, often with an associated mucinous adenoma of the appendix. There is evidence that the peritoneal lesions in PMP are clonally derived from the associated appendiceal adenoma. Little is known about the molecular genetic alterations or hereditary factors involved in the development of appendiceal mucinous tumors and PMP. We report the only known example of appendiceal mucinous adenomas in identical twin brothers, one of whom developed PMP. We analyzed the status of the K-RAS and APC genes in these tumors using digital polymerase chain reaction and digital single nucleotide polymorphism (SNP) assay. Identical K-RAS mutations were detected in the appendiceal adenoma and peritoneal tumor from the twin with PMP, whereas the adenoma from the other twin harbored a different mutation. Digital SNP analysis demonstrated loss of heterozygosity of APC only in the adenoma from the twin without PMP but not from the appendiceal or peritoneal tumors of the twin with PMP. The adjacent normal tissue in each case retained both APC alleles. The K-RAS mutational analysis supports the view that PMP is clonally derived from the associated appendiceal mucinous adenoma. The lack of loss of heterozygosity of APC in the adenoma and peritoneal tumor from the twin with PMP suggests that loss of heterozygosity of APC is not necessarily involved in the development of all appendiceal adenomas or PMP. The different types of mutations in K-RAS and the different allelic status of the APC locus in the tumors from both twins suggest that mutation in K-RAS and loss of heterozygosity of APC occurs somatically in adenomas and is independent of the identical genetic background of the twins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474297     DOI: 10.1097/00000478-200108000-00017

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 2.  Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei.

Authors:  Veena Ramaswamy
Journal:  Indian J Surg Oncol       Date:  2016-03-19

3.  High-level microsatellite instability in appendiceal carcinomas.

Authors:  Melissa W Taggart; John Galbincea; Paul F Mansfield; Keith F Fournier; Richard E Royal; Michael J Overman; Asif Rashid; Susan C Abraham
Journal:  Am J Surg Pathol       Date:  2013-08       Impact factor: 6.394

4.  Primary appendiceal mucinous adenocarcinoma in two first-degree relatives: case report and review.

Authors:  Adrianne R Racek; Kari G Rabe; Myra J Wick; Apostolos Psychogios; Noralane M Lindor
Journal:  Hered Cancer Clin Pract       Date:  2011-05-04       Impact factor: 2.857

5.  Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei.

Authors:  Mei Sim Lung; Catherine A Mitchell; Maria A Doyle; Andrew C Lynch; Kylie L Gorringe; David D L Bowtell; Ian G Campbell; Alison H Trainer
Journal:  BMC Cancer       Date:  2020-05-01       Impact factor: 4.430

6.  Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Authors:  Hakan Alakus; Michele L Babicky; Pradipta Ghosh; Shawn Yost; Kristen Jepsen; Yang Dai; Angelo Arias; Michael L Samuels; Evangeline S Mose; Richard B Schwab; Michael R Peterson; Andrew M Lowy; Kelly A Frazer; Olivier Harismendy
Journal:  Genome Med       Date:  2014-05-29       Impact factor: 11.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.